Luke Evnin
CIK 1134657 · Chief Executive Officer · last filed 2026-07-08
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
PCRX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 1100
BOSTON, MA 02116
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| HOWL | Director | 107,429 | $1.01 | $109.0K | -$845.3K | 38 | 2026-07-08 |
| TCR2 THERAPEUTICS INC. (TCRR) Delisted | 10%+ Owner | 3,745,148 | $1.48 | $5.54M | -$131.9K | 1 | 2023-05-24 |
| Oncorus, Inc. (ONCR) Delisted | Director | 2,492,843 | $0.12 | $300.5K | $2.27M | 3 | 2022-06-24 |
| iTeos Therapeutics, Inc. (ITOS) Delisted | 10%+ Owner | 3,377,687 | $10.15 | $34.28M | -$3.52M | 2 | 2021-09-23 |
| TURMERIC ACQUISITION CORP. (TMPMW) Delisted | Chief Executive Officer | — | $0.00 | — | $0 | 1 | 2021-04-30 |
| TURMERIC ACQUISITION CORP. (TMPMU) Delisted | Chief Executive Officer | 415,500 | $9.99 | $4.15M | $0 | 1 | 2020-10-20 |
| Harpoon Therapeutics, Inc. (HARP) Delisted | Director | 427,595 | $23.01 | $9.84M | $3.50M | 4 | 2020-06-01 |
| SNDX | Director | 1,138,210 | $9.70 | $11.03M | $0 | 5 | 2018-05-25 |
| RYTM | 10%+ Owner | 2,696,392 | $114.60 | $309.01M | $1.70M | 1 | 2017-10-11 |
| Radius Health, Inc. (RDUS) Delisted | 10%+ Owner | 3,887,502 | $30.00 | $116.63M | $0 | 2 | 2016-09-29 |
| ARATANA THERAPEUTICS, INC. (PETX) Delisted | 10%+ Owner | 38,386 | — | — | -$12.01M | 1 | 2014-03-12 |
| Epizyme, Inc. (EPZM) Delisted | 10%+ Owner | 2,413,819 | $1.47 | $3.55M | -$13.65M | 1 | 2014-02-11 |
| ReShape Weightloss Inc. (ETRM) Delisted | Director | 1,397,699 | — | — | $4.25M | 14 | 2014-01-09 |
| PCRX | Director | 844,566 | $36.45 | $30.79M | -$33.62M | 16 | 2013-06-13 |
| MBRX | Director | 105 | $8.87 | $931 | $168.2K | 4 | 2009-06-25 |
| OSCIENT PHARMACEUTICALS CORP (OSCI) Delisted | 10%+ Owner | 4,222 | — | — | $0 | 1 | 2009-05-29 |
| Pharmasset Inc (VRUS) Delisted | 10%+ Owner | 8,591 | — | — | -$5.77M | 4 | 2008-06-24 |
| PCS | 10%+ Owner | 837,441 | $49.42 | $41.39M | $0 | 1 | 2007-04-26 |
| SENORX INC (SENO) Delisted | 10%+ Owner | 2,242,379 | — | — | $0 | 1 | 2007-04-03 |
| CORNERSTONE THERAPEUTICS INC (CRTX) Delisted | 3,853,102 | $1.95 | $7.51M | $0 | 1 | 2007-02-15 | |
| MEMY | 10%+ Owner | 11,391,019 | $13.01 | $148.20M | $2.57M | 1 | 2007-01-05 |
Recent Filings · Page 4 of 11
108 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-10-29 | HOWL | Sell (S) | −177,145 | -$286.5K | EDGAR |
| 2025-06-13 | HOWL | Grant (A) | — | $0 | EDGAR |
| 2025-04-30 | HOWL | Mixed | +25,688 | -$16 | EDGAR |
| 2024-05-24 | HOWL | Grant (A) | — | $0 | EDGAR |
| 2023-06-23 | HOWL | Grant (A) | — | $0 | EDGAR |
| 2023-05-24 | TCR2 THERAPEUTICS INC. (TCRR) Delisted | Mixed | +108,099 | -$1 | EDGAR |
| 2022-06-24 | Oncorus, Inc. (ONCR) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-03 | HOWL | Grant (A) | — | $0 | EDGAR |
| 2021-09-23 | iTeos Therapeutics, Inc. (ITOS) Delisted | Sell (S) | −33,929 | -$933.0K | EDGAR |
| 2021-09-20 | iTeos Therapeutics, Inc. (ITOS) Delisted | Sell (S) | −91,254 | -$2.59M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.